<DOC>
	<DOCNO>NCT01730651</DOCNO>
	<brief_summary>This phase II study high dose intensity modulate radiation therapy cervical cancer metastatic lymphadenopathy initial diagnosis</brief_summary>
	<brief_title>High Dose Intensity Modulated Radiation Therapy Cervical Cancer With Metastatic Lymphadenopathies .</brief_title>
	<detailed_description>Lymph node ( LN ) involvement cervical cancer poor prognostic factor ( 1 ) . Although lymph node evaluation part International Federation Gynecology Obstetrics ( FIGO ) stag system ( 2 ) , generally perform one initial workup patient cervical cancer use modern imaging tool accurate evaluation disease extent possible treatment adjustment . Kidd et al report positron emission tomography [ 18F ] fluorodeoxyglucose ( FDG-PET ) -positive lymph node rate 47 % diagnosis 560 patient . They also show within stage , patient PET-positive lymph node significantly bad disease specific survival PET-negative lymph node ( p &lt; 0.001 ) ( 3 ) . Historically , dose escalation pelvic para-aortic metastatic lymphadenopathy give much attention primary uterine cervical lesion partly expect increased risk bowel toxicity conventional radiotherapy technique use . Unlike head neck cancer intensity modulate radiation therapy ( IMRT ) tomotherapy actively use treatment large lymphadenopathy show produce improved disease control ( 4 , 5 ) , similar study cervical cancer . It well know 60 Gy10 2Gy equivalent dose ( EQD2 , α/β=10 Gy ) need control gross tumor size 10 mm , contain 109 cell , accord logarithmic cell kill ( 6 ) . Theoretically , pelvic para-aortic LNs ( PAN ) could control dose 45-50 Gy10 EQD2 , need escalate dose much possible new radiation technology . In current study , evaluate LNs control rate , toxicity rate , progression-free survival overall survival cervical cancer patient lymphadenopathy treat high dose intensity modulate radiation therapy</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Patients ( adequately clinically stag ) primary , untreated , histologically confirm carcinoma uterine cervix ( include clear cell small cell carcinoma ) , metastatic lymphadenopathy ( pelvis PAN &gt; 1.5 cm short diameter , with/without biopsy proven inguinal lymph node [ ING ] ) 2 . Patients Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 3 . Patients adequate bone marrow function : absolute neutrophil count ( ANC ) great equal 1,500/mcl , platelet great equal 100,000/mcl beginning . 4 . Patients adequate renal function : creatinine equal less 2.0 mg % . 5 . Patients sign approve informed consent authorization 1 . Patients recurrent LN ( ) ( ) previously irradiate . 2 . Patients diagnosis malignance tumor except papillary follicular thyroid cancer skin cancer 3 . Patients metastatic lymphadenopathy pelvis , PAN , ING ( e.g . supraclavicular mediastinal metastatic lymphadenopathy ) 4 . Patients distant organ metastasis ( e.g . bone , lung , brain… )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cervical cancer metastatic lymphadenopathy</keyword>
</DOC>